Evidence map›Paper›PMID 42652161›Full record

ArticleBiomedicines2026

Treatment Persistence and Factors Associated with Bimekizumab Discontinuation in Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Multicenter Study.

Jose A Pinto-Tasende, Carlos Garcia-Porrua, Francisco Maceiras-Pan, Rafael B Melero-González, Angeles Hernandez Del Rio, Evelin Cecilia Cervantes Pérez, Victor Quevedo-Vila, Carlota L Iñiguez, Sara Alonso-Castro, Maria Caeiro-Aguado and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jose A Pinto-TasendeDepartment of Rheumatology-INIBIC, Complexo Hospitalario Universitario de A Coruña, 84 Xubias de Arriba Road, 15006 A Coruña, Spain.ORCID 0000-0002-4993-8185
Carlos Garcia-PorruaHospital Universitario Lucus Augusti, Rheumatology, 27003 Lugo, Spain.ORCID 0009-0001-4933-957X
Francisco Maceiras-PanComplexo Hospitalario Universitario Alvaro Cunqueiro, Rheumatology, 36312 Vigo, Spain.
Rafael B Melero-GonzálezComplexo Hospitalario Universitario Ourense, Rheumatology, 32005 Ourense, Spain.ORCID 0000-0002-7967-351X
Angeles Hernandez Del RioComplexo Hospitalario Universitario Arquitecto Marcide-Naval, Rheumatology, 15405 Ferrol, Spain.
Evelin Cecilia Cervantes PérezComplexo Hospitalario Universitario Pontevedra, Rheumatology, 36071 Pontevedra, Spain.ORCID 0000-0001-8108-6157
Victor Quevedo-VilaHospital Comarcal Monforte de Lemos, Rheumatology, 27400 Lugo, Spain.
Carlota L IñiguezHospital El Bierzo-Ponferrada, Rheumatology, 24404 León, Spain.ORCID 0000-0002-3051-389X
Sara Alonso-CastroHospital Universitario Central de Asturias, Rheumatology, 33011 Oviedo, Spain.
Maria Caeiro-AguadoComplexo Hospitalario Universitario Pontevedra, Rheumatology, 36071 Pontevedra, Spain.
Rubén QueiroHospital Universitario Central de Asturias, Rheumatology, 33011 Oviedo, Spain.ORCID 0000-0002-8418-7145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bimekizumabbiologic therapydrug survivaleffectivenessIL-17 inhibitorsobesitypersistencepsoriatic arthritisreal-world evidencetreatment discontinuation

Identifiers

PMID42652161
PMCPMC13509830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.